ReviewPharmacoEconomics2009
Methods for measuring temporary health States for cost-utility analyses.
Review in PharmacoEconomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- A systematic review of utility values for chemotherapy-related adverse events.PharmacoEconomics · 2013Pooled it
- An effectiveness-implementation hybrid trial study protocol targeting posttraumatic stress disorder and comorbidity.Implementation science : IS · 2016Trial
- Women's values and preferences for thromboprophylaxis during pregnancy: a comparison of direct-choice and decision analysis using patient specific utilities.Thrombosis research · 2015Trial
- EuroQol (EQ-5D) health utility scores for patients with migraine.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2011Trial
- Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology Appraisals.PharmacoEconomics · 2026Review
- Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews.PharmacoEconomics - open · 2026Review
- Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children-Targeted Literature Reviews.PharmacoEconomics · 2025Review
- Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis.PharmacoEconomics - open · 2025Article
- Modelling the Cost-Effectiveness of Diagnostic Tests.PharmacoEconomics · 2023Article
- Estimates of Quality-Adjusted Life-Year Loss for Injuries in the United States.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- Defining Utility Values for Chorea Health States in Patients with Huntington's Disease.Advances in therapy · 2022Article
- Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes.Patient related outcome measures · 2022Review
- Using Time Trade-Off Methods to Elicit Short-Term Utilities Associated with Treatments for Bulbar Urethral Stricture.PharmacoEconomics - open · 2019Article
- Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.Health and quality of life outcomes · 2019Article
- Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making.Current medical research and opinion · 2015Article
- Estimating utility values for vesicoureteral reflux in the general public using an online tool.Journal of pediatric urology · 2014Article
- How is the most severe health state being valued by the general population?Health and quality of life outcomes · 2014Article
- Is Health Related Quality of Life (HRQoL) a valid indicator for health systems evaluation?SpringerPlus · 2013Review
- Patient and societal value functions for the testing morbidities index.Medical decision making : an international journal of the Society for Medical Decision Making · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A variety of methods are available to measure preferences for temporary health states for cost-utility analyses. The objectives of this review were to summarize the available temporary health-state valuation methods, identify advantages and disadvantages of each, and identify areas for future research. We describe the key aspects of each method and summarize advantages and disadvantages of each method in terms of consistency with QALY theory, relevance to temporary health-state-specific domains, ease of use, time preference, and performance in validation studies. Two broad categories of methods were identified: traditional and adapted. Traditional methods were health status instruments, time trade-off (TTO), and the standard gamble (SG). Methods adapted specifically for temporary health-state valuation were TTO with specified duration of the health state, TTO with a lifespan modification, waiting trade-off, chained approaches for TTO and SG, and sleep trade-off. Advantages and disadvantages vary by method and no 'gold standard' method emerged. Selection of a method to value temporary health states will depend on the relative importance of the following considerations: ability to accurately capture the unique characteristics of the temporary health state, level of respondent burden and cognition, theoretical consistency of elicited preference values with the overall purpose of the study, and resources available for study development and data collection. Further research should focus on evaluating validity, reliability and feasibility of temporary health-state valuation methods.
Indexed as
Identifiers
19757865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.